{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:19:54Z","timestamp":1791566394916,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Psoriatic Arthritis (PsA) is an immune-mediated disease with heterogenous symptoms indicating differences in the underlying immunopathogenesis. The primary objective of the study explored the dynamic mechanisms and interplay between immune cell subtypes constituting the immune response driving PsA to evaluate possible differences in immune cellular phenotypes, and secondary examined associations between emerging immune cellular phenotypes and disease outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Peripheral blood was collected from 70 PsA patients. Frequencies of nine immune cell subtypes were determined by multicolor flow cytometry. The interplay between immune cells were examined with principal component analysis (PCA) to establish immune cellular phenotypes. Disease characteristics, Disease Activity in Psoriatic Arthritis (DAPSA) and Psoriasis Area Severity Index (PASI) were retrieved to examine associations to individual cellular phenotypes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Four components were identified using PCA resembling four immune cellular phenotypes. Component 1, explaining 25.6% of the variance with contribution from T-helper 17 cells (Th17), memory T regulatory cells (mTregs), dendritic cells and monocytes, was associated with longer disease duration and higher DAPSA. Component 2, driven by Th1, na\u00efve Tregs and mTregs, was associated with shorter disease duration. Component 3 was driven by both Th1, Th17 and CD8+ T cells, while component 4 was characterized by a reverse correlation between CD8+ T cells and natural killer cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Four immune cellular phenotypes of PsA were suggested at baseline demonstrating complex immune cellular mechanisms in PsA implying the possibility of improving PsA patient stratification based on both clinical and immune cellular phenotypes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-022-02956-x","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T07:34:44Z","timestamp":1669707284000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Four emerging immune cellular blood phenotypes associated with disease duration and activity established in Psoriatic Arthritis"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2676-4749","authenticated-orcid":false,"given":"Marie","family":"Skougaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisse B.","family":"Ditlev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zara R.","family":"Stisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ellegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Erik","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"issue":"10136","key":"2956_CR1","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273\u201384.","journal-title":"Lancet."},{"issue":"9","key":"2956_CR2","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/ard.2008.094946","volume":"68","author":"CT Ritchlin","year":"2009","unstructured":"Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68(9):1387\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2956_CR3","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1371\/journal.pmed.0030297","volume":"3","author":"D McGonagle","year":"2006","unstructured":"McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):1242\u20138.","journal-title":"PLoS Med"},{"issue":"SUPPL. 1","key":"2956_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1468-3083.2009.03363.x","volume":"23","author":"D McGonagle","year":"2009","unstructured":"McGonagle D. Enthesitis: An autoinflammatory lesion linking nail and joint involvement in psoriatic disease. J Eur Acad Dermatology Venereol. 2009;23(SUPPL. 1):9\u201313.","journal-title":"J Eur Acad Dermatology Venereol"},{"issue":"5966","key":"2956_CR5","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1126\/science.1178331","volume":"327","author":"F Geissmann","year":"2010","unstructured":"Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science (80- ). 2010;327(5966):656\u201361.","journal-title":"Science (80- )"},{"key":"2956_CR6","doi-asserted-by":"crossref","unstructured":"Qu N, Xu M, Mizoguchi I, Furusawa J, Kaneko K, Watanabe K, et al. Pivotal Roles of T-Helper 17-Related Cytokines, IL-17, IL-22, and IL-23, in Inflammatory Diseases. Clin Dev Immunol. 2013;2013(968549):1\u201313.","DOI":"10.1155\/2013\/968549"},{"issue":"SUPPL. 2","key":"2956_CR7","first-page":"26","volume":"64","author":"DJ Veale","year":"2005","unstructured":"Veale DJ, Ritchlin C, FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005;64(SUPPL. 2):26\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2956_CR8","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.autrev.2014.11.012","volume":"14","author":"M Diani","year":"2015","unstructured":"Diani M, Altomare G, Reali E. T cell responses in psoriasis and psoriatic arthritis. Autoimmun Rev. 2015;14(4):286\u201392.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"2956_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/imm.12142","volume":"141","author":"BW Kirkham","year":"2014","unstructured":"Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: A unique pathway in immune-mediated diseases: Psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2014;141(2):133\u201342.","journal-title":"Immunology."},{"issue":"January","key":"2956_CR10","first-page":"1","volume":"11","author":"N Rosine","year":"2021","unstructured":"Rosine N, Miceli-Richard C. Innate Cells: The Alternative Source of IL-17 in Axial and Peripheral Spondyloarthritis? Front Immunol. 2021;11(January):1\u201312.","journal-title":"Front Immunol"},{"issue":"5","key":"2956_CR11","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1002\/art.38376","volume":"66","author":"B Menon","year":"2014","unstructured":"Menon B, Gullick NJ, Walter GJ, Rajasekhar M, Garrood T, Evans HG, et al. Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheum. 2014;66(5):1272\u201381.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"2956_CR12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41584-020-00507-9","volume":"16","author":"DR Jadon","year":"2020","unstructured":"Jadon DR, Stober C, Pennington SR, FitzGerald O. Applying precision medicine to unmet clinical needs in psoriatic disease. Nat Rev Rheumatol. 2020;16(11):609\u201327.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"2956_CR13","first-page":"336","volume":"58","author":"I Miyagawa","year":"2019","unstructured":"Miyagawa I, Nakayamada S, Nakano K, Kubo S, Iwata S, Miyazaki Y, et al. Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatol (United Kingdom). 2019;58(2):336\u201344.","journal-title":"Rheumatol (United Kingdom)"},{"issue":"3","key":"2956_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/cei.12626","volume":"181","author":"DN Hull","year":"2015","unstructured":"Hull DN, Williams RO, Pathan E, Alzabin S, Abraham S, Taylor PC. Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis. Clin Exp Immunol. 2015;181(3):401\u20136.","journal-title":"Clin Exp Immunol"},{"key":"2956_CR15","doi-asserted-by":"crossref","unstructured":"Mehta H, Mashiko S, Angsana J, Rubio M, Hsieh YCM, Maari C, et al. Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab. J Invest Dermatol. 2021;141(7):1707\u201318.","DOI":"10.1016\/j.jid.2021.01.005"},{"issue":"March","key":"2956_CR16","doi-asserted-by":"publisher","first-page":"108425","DOI":"10.1016\/j.clim.2020.108425","volume":"215","author":"Y Liu","year":"2020","unstructured":"Liu Y, Jarjour W, Olsen N, Zheng SG. Traitor or warrior\u2013Treg cells sneaking into the lesions of psoriatic arthritis. Clin Immunol. 2020;215(March):108425.","journal-title":"Clin Immunol"},{"issue":"12","key":"2956_CR17","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.3899\/jrheum.110283","volume":"38","author":"SY Kawashiri","year":"2011","unstructured":"Kawashiri SY, Kawakami A, Okada A, Koga T, Tamai M, Yamasaki S, et al. CD4+CD25 highCD127 low\/- Treg cell frequency from peripheral blood correlates with disease activity in patients with rheumatoid arthritis. J Rheumatol. 2011;38(12):2517\u201321.","journal-title":"J Rheumatol"},{"issue":"4","key":"2956_CR18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.5021\/ad.2010.22.4.397","volume":"22","author":"WJ Yun","year":"2010","unstructured":"Yun WJ, Lee DW, Chang SE, Yoon GS, Huh JR, Won CH, et al. Role of CD4+CD25high+FOXP3+ regulatory T cells in psoriasis. Ann Dermatol. 2010;22(4):397\u2013403.","journal-title":"Ann Dermatol"},{"issue":"1","key":"2956_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.4049\/jimmunol.174.1.164","volume":"174","author":"H Sugiyama","year":"2005","unstructured":"Sugiyama H, Gyulai R, Toichi E, Garaczi E, Shimada S, Stevens SR, et al. Dysfunctional Blood and Target Tissue CD4 + CD25 high Regulatory T Cells in Psoriasis: Mechanism Underlying Unrestrained Pathogenic Effector T Cell Proliferation. J Immunol. 2005;174(1):164\u201373.","journal-title":"J Immunol"},{"issue":"6","key":"2956_CR20","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1002\/acr.23693","volume":"71","author":"P H\u00f8jgaard","year":"2019","unstructured":"H\u00f8jgaard P, Ellegaard K, Nielsen SM, Christensen R, Guldberg-M\u00f8ller J, Ballegaard C, et al. Pain Mechanisms and Ultrasonic Inflammatory Activity as Prognostic Factors in Patients With Psoriatic Arthritis: A Prospective Cohort Study. Arthritis Care Res. 2019;71(6):798\u2013810.","journal-title":"Arthritis Care Res"},{"issue":"3","key":"2956_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nri3158","volume":"12","author":"HT Maecker","year":"2012","unstructured":"Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol. 2012;12(3):191\u2013200.","journal-title":"Nat Rev Immunol"},{"key":"2956_CR22","doi-asserted-by":"crossref","unstructured":"Ye W, Lu W, Tang Y, Chen G, Li X, Ji C, et al. Identification of COVID-19 Clinical Phenotypes by Principal Component Analysis-Based Cluster Analysis. Front Med. 2020;7(November):1\u20137.","DOI":"10.3389\/fmed.2020.570614"},{"issue":"4","key":"2956_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0231227","volume":"15","author":"HJ Yoon","year":"2020","unstructured":"Yoon HJ, Kang J, Park H, Sohn I, Lee SH, Lee HY. Deciphering the tumor microenvironment through radiomics in non-small cell lung cancer: Correlation with immune profiles. PLoS One. 2020;15(4):1\u201313.","journal-title":"PLoS One"},{"issue":"4","key":"2956_CR24","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.csda.2004.06.015","volume":"49","author":"PR Peres-Neto","year":"2005","unstructured":"Peres-Neto PR, Jackson DA, Somers KM. How many principal components? stopping rules for determining the number of non-trivial axes revisited. Comput Stat Data Anal. 2005;49(4):974\u201397.","journal-title":"Comput Stat Data Anal"},{"issue":"1","key":"2956_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-017-1353-6","volume":"19","author":"JH Lee","year":"2017","unstructured":"Lee JH, Kim B, Jin WJ, Kim HH, Ha H, Lee ZH. Pathogenic roles of CXCL10 signaling through CXCR3 and TLR4 in macrophages and T cells: Relevance for arthritis. Arthritis Res Ther. 2017;19(1):1\u201314.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2956_CR26","first-page":"22","volume":"27","author":"A Antonelli","year":"2009","unstructured":"Antonelli A, Fallahi P, Delle Sedie A, Ferrari SM, Maccheroni M, Bombardieri S, et al. High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthtritis. Clin Exp Rheumatol. 2009;27(1):22\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"2956_CR27","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1002\/art.27622","volume":"62","author":"J Leipe","year":"2010","unstructured":"Leipe J, Grunke M, Dechant C, Reindl C, Kerzendorf U, Schulze-Koops H, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum. 2010;62(10):2876\u201385.","journal-title":"Arthritis Rheum"},{"issue":"22","key":"2956_CR28","first-page":"5166","volume":"21","author":"E Colombo","year":"2017","unstructured":"Colombo E, Galleri G, Erre GL, Piras C, Biondi G, Taras L, et al. Peripheral blood CD8+ T-cell profiles in patients with psoriatic arthritis: A cross-sectional case-control study. Eur Rev Med Pharmacol Sci. 2017;21(22):5166\u201371.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"2956_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-47310-5","volume":"9","author":"M Diani","year":"2019","unstructured":"Diani M, Casciano F, Marongiu L, Longhi M, Altomare A, Pigatto PD, et al. Increased frequency of activated CD8+ T cell effectors in patients with psoriatic arthritis. Sci Rep. 2019;9(1):1\u201310.","journal-title":"Sci Rep"},{"issue":"1","key":"2956_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-015-0640-3","volume":"17","author":"O FitzGerald","year":"2015","unstructured":"FitzGerald O, Haroon M, Giles JT, Winchester R. Concepts of pathogenesis in psoriatic arthritis: Genotype determines clinical phenotype. Arthritis Res Ther. 2015;17(1):1\u201311.","journal-title":"Arthritis Res Ther"},{"issue":"38","key":"2956_CR31","doi-asserted-by":"publisher","first-page":"27059","DOI":"10.1074\/jbc.M113.491530","volume":"288","author":"S Hu","year":"2013","unstructured":"Hu S, Liang S, Guo H, Zhang D, Li H, Wang X, et al. Comparison of the inhibition mechanisms of Adalimumab and Infliximab in treating tumor necrosis factor \u03b1-associated diseases from a molecular view. J Biol Chem. 2013;288(38):27059\u201367.","journal-title":"J Biol Chem"},{"issue":"5","key":"2956_CR32","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/bjd.16497","volume":"178","author":"C Paul","year":"2018","unstructured":"Paul C. Ixekizumab or secukinumab in psoriasis: what difference does it make? Br J Dermatol. 2018;178(5):1003\u20135.","journal-title":"Br J Dermatol"},{"issue":"6","key":"2956_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0128262","volume":"10","author":"M Dolcino","year":"2015","unstructured":"Dolcino M, Ottria A, Barbieri A, Patuzzo G, Tinazzi E, Argentino G, et al. Gene expression profiling in peripheral blood cells and synovial membranes of patients with psoriatic arthritis. PLoS One. 2015;10(6):1\u201333.","journal-title":"PLoS One"},{"issue":"4","key":"2956_CR34","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/art.38995","volume":"67","author":"J Belasco","year":"2015","unstructured":"Belasco J, Louie JS, Gulati N, Wei N, Nograles K, Fuentes-Duculan J, et al. Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis. Arthritis Rheum. 2015;67(4):934\u201344.","journal-title":"Arthritis Rheum"},{"key":"2956_CR35","doi-asserted-by":"crossref","unstructured":"O\u2019Brien-Gore C, Gray EH, Durham LE, Taams LS, Kirkham BW. Drivers of Inflammation in Psoriatic Arthritis: the Old and the New. Curr Rheumatol Rep. 2021;23(6):1\u201311.","DOI":"10.1007\/s11926-021-01005-x"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02956-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02956-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02956-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T18:05:35Z","timestamp":1669745135000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02956-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2956"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02956-x","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"assertion":[{"value":"24 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki with ethical approval obtained from the Danish Ethical Committee of the Capital Region of Denmark (J.no.: H-18024568), and the General Data Protection Regulation approved by the Capital Region of Denmark (J.no.: BFH-2015-043). All patients provided written informed consent before inclusion. The Parker Institute\u2019s PsA patient cohort\u00a0study was registered at  (NCT02572700). A pre-specified protocol is publicly available at the Parker Institute\u2019s website ().","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Marie Skougaard has received research funding from, the Danish Rheumatism Association, the Danish National Psoriasis Foundation, and Pfizer that is besides the funding already disclosed under fundingSisse B. Ditlev has no conflicts of interestZara R. Stisen has no conflicts of interestLaura C. Coates has received honoraria, grant\/research support or consulting fees from AbbVie, Amgen, Boehringer-Ingelheim, BMS, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Sun Pharma, and UCB; and is a member of a speakers\u2019 bureau for AbbVie, Amgen, Biogen, BMS, Celgene, Eli Lilly, Janssen, Medac, Novartis, Pfizer, Sun Pharma, and UCBKaren Ellegaard has no conflicts of interestLars Erik Kristensen has received fees for speaking and consultancy from AbbVie, Amgen, Biogen, Bristol Myers Squibb, Eli Lilly, Gilead, Janssen, MSD, Novartis, Pfizer, and UCB. And IIT grants from Biogen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"262"}}